fashion -WSS

fashion

author：explore 2025-10-02 09:35:34 Page View：2

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Influencer to be charged after chaos erupts in New York City's Union Square
Next article： Duchenne breakthrough therapy leaves behind pioneering families

leisure time

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

2 US Navy sailors arrested for allegedly spying for China

2:23TheWasp-classamphibiousassaultshipUSSEssex(LHD2)transitstheArabianGulfonOct.9,2015.U.S.NavyPhoto

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

For AI in health care standards, federal regulators join with industry group

AdobeAtfirstglance,theCoalitionforHealthAIlookslikeanytechnologylobbyinggroup.Itsmembership—includin

fashion

focus

leisure time

For AI in health care standards, federal regulators join with industry group